Drug intelligence / Profile preview

LK-Neo ACT

Development stage: Preclinical
Lead developer: Likang Life Sciences Holdings
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

LK-Neo ACT is a neoantigen-specific adoptive T cell therapy developed by Likang Life Sciences (Beijing Likang Life Technology Co., Ltd.) for the treatment of cancer. It is classified as an antineoplastic and immunotherapy agent, specifically a T-lymphocyte cell therapy. The mechanism of action involves immunologic cytotoxicity and T lymphocyte replacement, aiming to target tumor-specific neoantigens in neoplasms. As of the latest updates, it is in preclinical development for cancer indications[1][2].

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on LK-Neo ACT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LK-Neo ACT.

Explore the full profile